Summary
- Shares of psychiatric medicine concern NRx Pharmaceuticals, Inc. have more than doubled off their mid-2022 sub-$1 lows as the company refocuses on its NRX-101 program.
- A detour into Covid-19 meds proved fruitless but has provided investors with a fairly compelling risk-reward scenario.
- With a Phase 2 data readout in 1Q23, a pivotal Phase 3 readout in 3Q23, and enough cash to get to YE23, the recent insider buying merited a deeper dive.
- An investment analysis follows in the paragraphs below.
For further details see:
NRx Pharmaceuticals: A Speculative, Binary Play